Effects of sodium in hydration solution on plasma methotrexate concentrations following high-dose methotrexate in children with acute lymphoblastic leukemia

Cancer Chemotherapy and Pharmacology

Volumn 51, Issue 3, 2003, Pages 256-260

  Kinoshita, Akitoshi ^a,b   Kurosawa, Yoshihiro ^b   Kondoh, Kensuke ^b   Suzuki, Toshio ^b   Manabe, Atsushi ^c   Inukai, Takeshi ^d   Sugita, Kanji ^d   Nakazawa, Shinpei ^d  

^a ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

^d UNIVERSITY OF YAMANASHI   (Japan)

Author keywords

Glomerular filtration rate; High dose methotrexate; Hydration; Nephrotoxicity; Sodium

Indexed keywords

ASPARAGINASE; CYTARABINE; FOLINIC ACID; HYDROCORTISONE; METHOTREXATE; PIRARUBICIN; PREDNISOLONE; SODIUM; SOLITA T3; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG MEGADOSE; FEMALE; GASTROINTESTINAL SYMPTOM; GLOMERULUS FILTRATION RATE; GRANULOCYTOPENIA; HUMAN; HYDRATION; INFECTION; LEUKOPENIA; LIVER TOXICITY; LOW DRUG DOSE; MALE; NAUSEA; NEPHROTOXICITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SODIUM BLOOD LEVEL; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

EID: 0037361923     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-002-0565-9     Document Type: Article

References (23)

1. Stoller RG, Hande KR, Jacobs SA, Rosenberg SA, Chabner BA (1977) The use of plasma pharmacokinetics to predict and prevent methotrexate toxicity. N Engl J Med 297:630
2. Evans WE, Pratt CB, Taylor RH, Barker LF, Crom WR (1979) Pharmacokinetic monitoring of high-dose methotrexate. Early recognition of high-risk patients. Cancer Chemother Pharmacol 3:161
3. Frei E 3rd, Blum RH, Pitman SW, Kirkwood JM, Henderson IC, Skarin AT, Mayer RJ, Bast RC, Garnick MB, Parker LM, Canellos GP (1980) High-dose methotrexate with leucovorin rescue. Rationale and spectrum of antitumor activity. Am J Med 68:370
4. Jolivet J, Cowan KH, Curt GA, Clendeninn NJ, Chabner BA (1983) The pharmacology and clinical use of methotrexate. N Engl J Med 309:1094
5. Fox RM (1979) Methotrexate nephrotoxicity. Clin Exp Pharmacol Physiol 5:43-45
6. Schilsky RL (1982) Renal and metabolic toxicities of cancer chemotherapy. Semin Oncol 9:75
7. Christensen ML, Rivera GK, Crom WR, Hancock ML, Evans WE (1988) Effect of hydration on methotrexate plasma concentrations in children with acute lymphocytic leukemia. J Clin Oncol 6:797
8. Relling MV, Fairclough D, Ayers D, Crom WR, Rodman JH, Pui CH, Evans WE (1994) Patient characteristics associated with high-risk methotrexate concentrations and toxicity. J Clin Oncol 12:1667
9. Howell SB, Tamerius RK (1980) Achievement of long duration methotrexate exposure with concurrent low dose thymidine protection: influence on methotrexate pharmacokinetics. Eur J Cancer 16:1427
10. Abelson HT, Fosburg MT, Beardsley GP, Goorin AM, Gorka C, Link M, Link D (1983) Methotrexate-induced renal impairment: clinical studies and rescue from systemic toxicity with high-dose leucovorin and thymidine. J Clin Oncol 1:208
11. Glode LM, Pitman SW, Ensminger WD, Rosowsky A, Papathanasopoulos N, Frei E 3rd (1979) A phase 1 study of high doses of aminopterin with leucovorin rescue in patients with advanced metastatic tumors. Cancer Res 39:3707
12. Howell SB, Carmody J (1977) Changes in glomerular filtration associated with high-dose methotrexate therapy in adults. Cancer Treat Rep 61:1389
13. Hande KR, Donehower RC, Chabner BA (1978) Pharmacology and pharmacokinetics of high dose methotrexate in man. In: Pinedo HM (ed) Clinical pharmacology of antineoplastic drugs. Elsevier/North Holland, New York
14. Carlson MA, Condon RE (1994) Nephrotoxicity of amphotericin B. J A Coll Surg 179:361
15. Branch RA (1988) Prevention of amphotericin B-induced renal impairment - a review on the use of sodium supplementation. Arch Intern Med 148:2389
16. World Health Organization (1979) Handbook for reporting results of cancer treatment (WHO offset publication no. 48). World Health Organization, Geneva
17. Evans WE, Hutson PR, Stewart CF, Cairnes DA, Bowman WP, Rivera G, Crom WR (1983) Methotrexate cerebrospinal fluid and serum concentrations after intermediate-dose methotrexate infusion. Clin Pharmacol Ther 33:301
18. Seidel H, Andersen A, Kvaloy JT, Nygaard R, Moe PJ, Jacobsen G, Lindqvist B, Slordal L (2000) Variability in methotrexate serum and cerebrospinal fluid pharmacokinetics in children with acute lymphocytic leukemia: relation to assay methodology and physiological variables. Leuk Res 24:193
19. Wang YM, Sutow WW, Romsdahl MM, Perez C (1979) Age-related pharmacokinetics of high-dose methotrexate in patients with osteosarcoma. Cancer Treat Rep 63:405
20. Wall AM, Gajjar A, Link A, Mahmoud H, Pui CH, Relling MV (2000) Individualized methotrexate dosing in children with relapsed acute lymphoblastic leukemia. Leukemia 14:221
21. Seidel H, Moe PJ, Nygaard R, Nygaard K, Brede W, Borsi JD (1994) Evaluation of serious adverse events in patients treated with protocols including methotrexate infusions. Pediatr Hematol Oncol 11:165
22. Evans WE, Crom WR, Abromowitch M, Dodge R, Look AT, Bowman WP, George SL, Pui CH (1986) Clinical pharmaco-dynamics of high-dose methotrexate in acute lymphocytic leukemia: identification of a relation between concentration and effect. N Engl J Med 314:471
23. Graf N, Winkler K, Betlemovic M, Fuchs N, Bode U (1994) Methotrexate pharmacology and prognosis in osteosarcoma. J Clin Oncol 12:1443